Is PepGen Inc. (PEPG) a Buy, Sell, or Hold?
NASDAQ : PEPG
PepGen Inc. — News
$2.85 USD
$0.44 (18.26%)
- Volume
- 3.21M
- Average Volume
- 842.17K
- Market Capitalization
- $197.13M
- P/E Ratio
- -1.90
- Dividend Yield
- 0.00%
- Price Target
- $5.50
- Year High
- $7.80
- Year Low
- $1.01
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $13.36
| Source | Headline |
|---|---|
|
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the gurufocus.com - 2026-08-06 08:00:00 |
|
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
[url="]PepGen Inc.[/url] (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of tran gurufocus.com - 2026-08-06 08:00:00 |
|
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
BOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights. businesswire.com - 2026-08-06 07:32:00 |
|
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
BOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen to Advance PGN-EDODM1 into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review. businesswire.com - 2026-08-06 07:30:00 |
|
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-b. businesswire.com - 2026-05-21 07:00:00 |
|
PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
PepGen (PEPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. zacks.com - 2026-05-20 10:35:25 |
|
PepGen (PEPG) Upgraded to Buy: Here's What You Should Know
PepGen (PEPG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 2026-05-13 13:01:21 |
|
PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended March 31, 2026, and recent corporate highlights. "We made encouraging progress during the first quarter of 2026 in our FREEDOM2-DM1 trial. The 5 mg/kg cohort — the in. businesswire.com - 2026-05-12 16:05:00 |
